Matches in Wikidata for { <http://www.wikidata.org/entity/Q66029301> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q66029301 description "clinical trial" @default.
- Q66029301 description "ensayu clínicu" @default.
- Q66029301 description "klinisch onderzoek" @default.
- Q66029301 description "клінічне випробування" @default.
- Q66029301 name "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks" @default.
- Q66029301 name "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks" @default.
- Q66029301 type Item @default.
- Q66029301 label "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks" @default.
- Q66029301 label "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks" @default.
- Q66029301 prefLabel "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks" @default.
- Q66029301 prefLabel "Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks" @default.
- Q66029301 P1050 Q66029301-C18A65BE-B71A-4788-9BB6-8F939BA76AE8 @default.
- Q66029301 P1132 Q66029301-CD25EA07-C857-451F-9745-D571BF0F242E @default.
- Q66029301 P1476 Q66029301-98F098F6-1318-43AE-B4E7-11E76C9A655B @default.
- Q66029301 P17 Q66029301-01B59D68-8974-4120-A18E-007FB1BC4A96 @default.
- Q66029301 P17 Q66029301-1E2BA628-D96E-4DF6-BE9C-6DFCB3B9547E @default.
- Q66029301 P17 Q66029301-21AB43C8-8485-43B1-AD29-13DAA086E3AD @default.
- Q66029301 P17 Q66029301-37CB19C1-55F2-409C-A595-7B7CCA6D1316 @default.
- Q66029301 P17 Q66029301-52C90E39-C7F8-4358-AB8D-3E9100EB6BCF @default.
- Q66029301 P17 Q66029301-835B2F2F-7532-4ED3-91E0-18782E37414B @default.
- Q66029301 P17 Q66029301-93349E8A-5240-4445-84F0-B72D5CE5C9BC @default.
- Q66029301 P17 Q66029301-A906177A-7B86-44B0-ABEA-4DBAB4994F30 @default.
- Q66029301 P17 Q66029301-D3D4636B-F8AE-49E9-A8A4-647508776D12 @default.
- Q66029301 P2899 Q66029301-D1D3D050-59BD-4206-8B57-1FF7904C4616 @default.
- Q66029301 P3098 Q66029301-58C8065B-4902-44C6-A60B-EF8F6B6BEC74 @default.
- Q66029301 P31 Q66029301-D1E40A75-6D05-46E1-B440-162A7C4D8F03 @default.
- Q66029301 P4135 Q66029301-7226DF4C-7A63-4544-886A-13DAB3A44321 @default.
- Q66029301 P580 Q66029301-1A346990-60EF-42FE-8E3F-44A7AC71F2E4 @default.
- Q66029301 P582 Q66029301-5B696032-99F4-4C03-9989-01C2EEB736FD @default.
- Q66029301 P6099 Q66029301-03FBA9E7-3B95-4A4A-88CC-644424658CD9 @default.
- Q66029301 P6153 Q66029301-16ED63CB-B60D-4755-BCB0-CDCD50815B46 @default.
- Q66029301 P8363 Q66029301-6658105E-0236-4CCD-90BD-8A311703F20D @default.
- Q66029301 P1050 Q170990 @default.
- Q66029301 P1132 "+264" @default.
- Q66029301 P1476 "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis" @default.
- Q66029301 P17 Q155 @default.
- Q66029301 P17 Q16 @default.
- Q66029301 P17 Q183 @default.
- Q66029301 P17 Q214 @default.
- Q66029301 P17 Q29 @default.
- Q66029301 P17 Q30 @default.
- Q66029301 P17 Q31 @default.
- Q66029301 P17 Q38 @default.
- Q66029301 P17 Q96 @default.
- Q66029301 P2899 "+18" @default.
- Q66029301 P3098 "NCT00147498" @default.
- Q66029301 P31 Q30612 @default.
- Q66029301 P4135 "+70" @default.
- Q66029301 P580 "2005-01-01T00:00:00Z" @default.
- Q66029301 P582 "2006-06-01T00:00:00Z" @default.
- Q66029301 P6099 Q42824440 @default.
- Q66029301 P6153 Q206921 @default.
- Q66029301 P8363 Q78089383 @default.